Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company's lipid ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Alnylam Pharma (ALNY) Prices 5.6M Share Common Offering at $125/ShNovember 14, 2017 5:48 AM Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)November 13, 2017 5:22 PM